Case Report: Two Cases Of Partial Response to Anti-EGFR Antibody-drug Conjugate Plus PD-1 Blockade in Advanced Penile Squamous Cell Carcinoma
Background Advanced penile squamous cell carcinoma (PSCC) is a rare malignancy with limited effective systemic treatment options. The development of new treatment strategies is therefore particularly important in this setting. Case presentation We report two cases diagnosed with advanced PSCC and bilateral inguinal lymph node metastases. The tumor was EGFR-positive, HPV-negative, and had a PD-L1 tumor proportion score of 1%, a TP53 p.Q317* mutation, low tumor mutational burden, and microsatellite-stable status. After thorough and extensive communication, the patients and their families agreed to assume the risks and requested first-line therapy with an anti-EGFR ADC (Becotatug Vedotin) plus a PD-1 inhibitor (Pucotenlimab). After treatment, the patients achieved a partial response according to RECIST v1.1, accompanied by marked clinical regression of the inguinal lesion. Treatment-related adverse events were limited to manageable grade 1 decreased appetite, rash, fatigue, and hepatic dysfunction. Conclusions These cases suggest that anti-EGFR ADC plus PD-1 inhibition may represent a feasible and biologically rational first-line treatment option for advanced PSCC. Further prospective evaluation of this strategy is warranted.
Authors
- Jiayao Wang (ORCID: https://orcid.org/0000-0003-2753-6000)
- Hongshuai Li (ORCID: https://orcid.org/0000-0002-9793-0540)
- Ruizhi Liu (ORCID: https://orcid.org/0000-0002-3386-7765)
- Jiaqi Liu (ORCID: https://orcid.org/0000-0002-9775-2342)
- Mingyi Zhang (ORCID: https://orcid.org/0000-0002-1695-7400)
- Ji-Yan Liu
- Li-Li Yang
- Shuang Zhang
Institutions
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-18
- DOI
- https://doi.org/10.21203/rs.3.rs-11268602/v1
- Primary Topic
- Genital Health and Disease
- Type
- preprint